Unlisted
| Company Name | 올릭스 주식회사 |
| English Name | OliX Pharmaceuticals, Inc. |
| Business Reg. No. | 1248690516 |
| CEO | 이동기 |
| Address | 경기도 성남시 수정구 고등동 608-3 - |
| Industry | 의학 및 약학 연구개발업 |
| Industry Code | 70113 |
| Established | Contact |
| Phone | 031-779-8400 |
| Website | www.olixpharma.com |
| Regular Employees | 76persons |
| Corp. Reg. No. | 1358110177957 |
Venture Certified
| 기술평가보증기업(기금) | 2010-09-17 ~ 2012-09-16 | 20100106826 | 2010-09-17 |
| 기술평가보증기업(기금) | 2012-09-17 ~ 2014-09-16 | 20120108967 | 2010-09-17 |
| 기술평가보증기업(기금) | 2014-09-17 ~ 2016-09-16 | 20140111146 | 2010-09-17 |
| 벤처투자유형 | 2016-09-17 ~ 2018-09-16 | 20160300405 | 2010-09-17 |
| 벤처투자유형 | 2018-09-17 ~ 2020-09-16 | 20180300638 | 2010-09-17 |
| 연구개발유형 | 2020-09-17 ~ 2022-09-16 | 20200111459 | 2010-09-17 |
| 벤처투자유형 | 2022-09-17 ~ 2025-09-16 | 20220818010029 | 2010-09-17 |
| 벤처투자유형 | 2025-09-17 ~ 2028-09-16 | 20250903010014 | 2010-09-17 |
Revenue CAGR -22.7%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 57B | 164B | 95B |
| Operating Profit | -257B | -179B | -226B |
| Net Profit | -415B | -190B | -211B |
| Total Assets | 739B | 1,009B | 1,307B |
| Total Liabilities | 565B | 503B | 632B |
| Total Equity | 174B | 506B | 675B |
Operating Loss: Op. profit -257B
Revenue down 65% YoY
3 Consecutive Years of Net Loss
Debt Ratio Surge (+225pp YoY)
▼ 56.2%
▼ 27.0%
▼ 160.9%
▲ 236.1%
▼ 592.6%
| Name | Position | Role |
|---|---|---|
| 이동기 | 대표이사 | 대표 |
| NPS Subscribers | 76persons |
| CEO | 이동기 |
| Est. Avg. Annual Salary | 6,10410K (50910K/mo) |
| Hired (12 mo) | +4persons |
| Left (12 mo) | -0persons |
| Net Change (12 mo) | +4persons |
| NPS Join Date | 2010-03-01 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
2 Additional Data Sources
{
"address": "경기 성남시",
"ceo_name": "이동기",
"certificate": [
{
"cert_number": "20100106826",
"changes": "",
"disclosure_date": "2010-09-17",
"first_cert_date": "2010-09-17",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2010-09-17 ~ 2012-09-16"
},
{
"cert_number": "20120108967",
"changes": "",
"disclosure_date": "2012-11-15",
"first_cert_date": "2010-09-17",
"no": "2",
"type": "기술평가보증기업(기금)",
"valid_period": "2012-09-17 ~ 2014-09-16"
},
{
"cert_number": "20140111146",
"changes": "",
"disclosure_date": "2014-10-14",
"first_cert_date": "2010-09-17",
"no": "3",
"type": "기술평가보증기업(기금)",
"valid_period": "2014-09-17 ~ 2016-09-16"
},
{
"cert_number": "20160300405",
"changes": "",
"disclosure_date": "2016-08-18",
"first_cert_date": "2010-09-17",
"no": "4",
"type": "벤처투자유형",
"valid_period": "2016-09-17 ~ 2018-09-16"
},
{
"cert_number": "20180300638",
"changes": "",
"disclosure_date": "2018-09-20",
"first_cert_date": "2010-09-17",
"no": "5",
"type": "벤처투자유형",
"valid_period": "2018-09-17 ~ 2020-09-16"
},
{
"cert_number": "20200111459",
"changes": "",
"disclosure_date": "2020-09-01",
"first_cert_date": "2010-09-17",
"no": "6",
"type": "연구개발유형",
"valid_period": "2020-09-17 ~ 2022-09-16"
},
{
"cert_number": "20220818010029",
"changes": "",
"disclosure_date": "2022-08-18",
"first_cert_date": "2010-09-17",
"no": "7",
"type": "벤처투자유형",
"valid_period": "2022-09-17 ~ 2025-09-16"
},
{
"cert_number": "20250903010014",
"changes": "",
"disclosure_date": "2025-09-03",
"first_cert_date": "2010-09-17",
"no": "8",
"type": "벤처투자유형",
"valid_period": "2025-09-17 ~ 2028-09-16"
}
],
"company_name": "올릭스 주식회사",
"financials": {
"2022": {
"capital_stock": 8351584000,
"cost_of_sales": 0,
"current_assets": 62003630000,
"current_liabilities": 40059991000,
"gross_profit": 9490673000,
"net_income": -21082020000,
"net_income_bs": -19991318000,
"non_current_assets": 68714095000,
"non_current_liabilities": 23128540000,
"non_operating_expenses": 8529167000,
"non_operating_income": 10096957000,
"operating_profit": -22649810000,
"revenue": 9490673000,
"sga_expenses": 32140482000,
"total_assets": 130717725000,
"total_equity": 67529195000,
"total_liabilities": 63188531000
},
"2023": {
"capital_stock": 8446735000,
"cost_of_sales": 0,
"current_assets": 27363996000,
"current_liabilities": 7251059000,
"gross_profit": 16434778000,
"net_income": -18981429000,
"net_income_bs": -19862434000,
"non_current_assets": 73536967000,
"non_current_liabilities": 43007671000,
"non_operating_expenses": 7742875000,
"non_operating_income": 6629125000,
"operating_profit": -17867679000,
"revenue": 16434778000,
"sga_expenses": 34302457000,
"total_assets": 100900963000,
"total_equity": 50642233000,
"total_liabilities": 50258730000
},
"2024": {
"capital_stock": 9229787000,
"cost_of_sales": 0,
"current_assets": 11543116000,
"current_liabilities": 33780381000,
"gross_profit": 5677152000,
"net_income": -41477860000,
"net_income_bs": -41008938000,
"non_current_assets": 62388956000,
"non_current_liabilities": 22716238000,
"non_operating_expenses": 21252676000,
"non_operating_income": 5502804000,
"operating_profit": -25727988000,
"revenue": 5677152000,
"sga_expenses": 31405140000,
"total_assets": 73932072000,
"total_equity": 17435454000,
"total_liabilities": 56496619000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "9,999,989,317",
"changes": "9,999,989,317",
"date": "2022-05-31"
},
{
"amount": "1,000,000,000",
"changes": "1,000,000,000",
"date": "2022-05-31"
},
{
"amount": "1,000,000,000",
"changes": "1,000,000,000",
"date": "2022-05-31"
},
{
"amount": "5,100,000,000",
"changes": "5,100,000,000",
"date": "2022-05-31"
},
{
"amount": "4,900,000,000",
"changes": "4,900,000,000",
"date": "2022-05-31"
},
{
"amount": "4,000,000,000",
"changes": "4,000,000,000",
"date": "2022-05-31"
},
{
"amount": "6,000,000,000",
"changes": "6,000,000,000",
"date": "2022-05-31"
},
{
"amount": "10,000,000,000",
"changes": "10,000,000,000",
"date": "2022-05-31"
},
{
"amount": "1,312,839,000",
"changes": "1,312,839,000",
"date": "2017-11-22"
}
],
"phone": "031-779-****",
"source": "pg_migration"
}{
"address": "경기도 성남시 수정구 대왕판교로",
"brno": "124869****",
"cappedWarning": false,
"companyName": "올릭스주식회사",
"estimatedAvgAnnualSalary": 61039644,
"estimatedAvgMonthlySalary": 5086637,
"fetchedAt": "2026-03-05T11:38:41.294Z",
"industryCode": "000000",
"industryName": "해당없음",
"joinDate": "20100301",
"last12MonthsHired": 4,
"last12MonthsLeft": 0,
"last12MonthsNetChange": 4,
"leaveDate": null,
"monthlyPensionAmount": 36725520,
"monthlyTrend": [
{
"lostSubscribers": 0,
"newSubscribers": 4,
"yearMonth": null
}
],
"npsRateUsed": 0.095,
"npsUpperCap": 6370000,
"seq": "6414223",
"status": "1",
"styleCode": "1",
"subscriberCount": 76,
"turnoverMonths": 1
}Data Quality: 95/10 | Primary Source: Venture System | Section Coverage: 8/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | DART | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | DART | Collected |
| Employment | Public Data | Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| Venture System Detail | 2026-03-05 | Collected |
| nps | 2026-03-05 | Collected |
| DART Financial | 2026-02-26 | Collected |
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |